Can a lower drug dose improve life after stem cell transplant for older adults?
NCT ID NCT06799195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard high dose of a drug (cyclophosphamide) with a lower dose, both combined with another drug (sirolimus), to prevent graft-versus-host disease (GVHD). The goal is to see if the lower dose helps patients feel better and have a higher quality of life after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cyclophosphamide (attenuated dose) and Sirolimus
What this could lead to
If successful, this could lead to a safer way to prevent graft-versus-host disease after stem cell transplants, improving quality of life for older adults with blood cancers.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. The lower drug dose might not prevent GVHD as effectively, and side effects are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••